Pharmafile Logo

VJOncology

Roche Basel Switzerland

Roche trumpets APHINITY data, but did it hit the mark?

Results raise questions about benefit of combining Herceptin with Perjeta

- PMLiVE

AZ’s Lynparza shows PARP inhibitor potential in breast cancer

Findings were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago

Richard Head nominated for EphMRA Award

We are delighted to announce that Research Partnership’s Director Richard Head has been nominated for The EphMRA President’s Award for Contribution to Pharmaceutical Market Research.According to EphMRA, Richard has been...

Inizio

Research Partnership launches new patient Living With Non-alcoholic Steatohepatitis (NASH) report

Living with Non-alcoholic Steatohepatitis (NASH) is a study conducted amongst 100 adults with NASH in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase...

Inizio

EULAR Annual European Congress of Rheumatology 2017

Join us at EULAR Congress 2017 in Madrid, 14-17 June

Inizio

- PMLiVE

Practice-changing data for J&J’s Zytiga in prostate cancer

LATITUDE study shows combined drug therapy reduces death risk by 38%

Eli Lilly HQ

Lilly adds to data backing breast cancer candidate abemaciclib

US pharma giant’s drug achieves PFS rate of 16.4 months

16 Generation Now

The impact of the millennial healthcare professional on our world

Havas Lynx

- PMLiVE

Germany’s Ventaleon names biotech entrepeneur CEO

Dr Ulrich Dauer joins group from OMEICOS

- PMLiVE

Constellation Pharmaceuticals appoints Jigar Raythatha as CEO

US firm has also bolstered its scientific advisory board

- PMLiVE

‘Nothing about us without us’

Why patient engagement is essential throughout the entire product life cycle

Healthcare Heroes – The Passion Project by Havas Lynx

The Havas Lynx group are incredibly proud to launch ’Healthcare Heroes, the passion project.’ This campaign shares inspirational stories from doctors, nurses, patients, pioneers, and entrepreneurs, who are all dedicated...

Havas Lynx

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links